Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Venous thromboembolism in patients with essential thrombocythemia and polycythemia vera.

Leukemia - 1 Apr 2012

Reikvam H, Tiu R V

Abstract excerpt

Polycythemia vera (PV) and essential thrombocythemia (ET) are myeloproliferative neoplasms (MPNs), which generally follow a benign and indolent clinical course. However, venous thromboses are common and constitute the main cause of morbidity and mortality. The discovery of the JAK2V617F mutation and other biomarkers has advanced our understanding of these diseases. There is a strong association between the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to JAK2 gene
Share to Janus Kinase 2
Share to Mutation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Phlebotomy

Share to Polycythemia Vera

Share to Risk Factors

Share to Thrombocythemia, Essential

Share to Venous Thromboembolism

Source

Identifiers

PMID: 22076463
DOI: 10.1038/leu.2011.314

Genes

JAK2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Venous thromboembolism in patients with essential thrombocythemia and polycythemia vera.PMID 22076463Read ↗

Insights into the pathogenesis and management of thrombosis in polycythemia vera and essential thrombocythemia.Semantic proximity Read ↗

Thrombosis-Driven Disease Progression in JAK2-Mutant Polycythemia Vera and Essential Thrombocythemia: Reassessing Risk-Based Management.Semantic proximity Read ↗

Essential thrombocythaemia: A contemporary approach with new drugs on the horizon.Semantic proximity Read ↗

JAK2 mutation-related disease and thrombosis.Semantic proximity Read ↗

Evidence and expertise in the management of polycythemia vera and essential thrombocythemia.Semantic proximity Read ↗

Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients.Semantic proximity Read ↗

Prevention of recurrent thromboembolism in myeloproliferative neoplasms: review of literature and focus on direct oral anticoagulants.Semantic proximity Read ↗

Thrombocytosis and thrombosis.Semantic proximity Read ↗

Prognostic risk model for patients with high-risk polycythemia vera and essential thrombocythemia.Semantic proximity Read ↗

[Thrombosis in myeloproliferative neoplasms].Semantic proximity Read ↗

Essential thrombocythemia.Semantic proximity Read ↗

Thrombotic and bleeding complications in classical myeloproliferative neoplasms.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.